<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348139</url>
  </required_header>
  <id_info>
    <org_study_id>D0570C00011</org_study_id>
    <secondary_id>2011-000133-37</secondary_id>
    <nct_id>NCT01348139</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered Via Single Inhalation Device Compared to AZD3199 Administered Via Turbuhaler™ Inhaler in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of single
      doses of three different dry powder inhalation formulations of AZD3199 administered via
      Single Inhalation Device (SID) compared to AZD3199 administered via Turbuhaler™ Inhaler and
      compared to placebo in patients with persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emax: Maximum Value of FEV1 for Every Treatment Visits</measure>
    <time_frame>0-24 hrs</time_frame>
    <description>Peak effect (Emax) within 0-24 hours of FEV1, for treatment visits 2 to 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E22-26h: The Average of the FEV1 Values Between 22 and 26 h for Every Treatment Visit</measure>
    <time_frame>22-26 hrs.</time_frame>
    <description>Trough effect (E22-26h) will be computed from the repeated measurements collected after each single dose during 22-26 hours of FEV1 from visit 2 to 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tEmax: Time to Maximum Value of FEV1 for Every Treatment Visit</measure>
    <time_frame>0 - 24 hrs.</time_frame>
    <description>Time to peak effect (tEmax), within 0-24 hours of FEV1, for treatment visits 2 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E5min: The Value of FEV1 at 5 Min for Every Treatment Visit.</measure>
    <time_frame>FEV1 at 5 min</time_frame>
    <description>Onset of effect (E5min), observed at 5 min. FEV1 for treatment visits 2 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E0-24h: The Average of the FEV1 Values Between 0 and 24 h for Every Treatment Visit</measure>
    <time_frame>0 - 24 hrs</time_frame>
    <description>Average effect over 0-24 hours of FEV1 (E0-24h), for treatment visits 2 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emax: Maximum Value of Pulse for Every Treatment Visits</measure>
    <time_frame>0 - 4 hrs.</time_frame>
    <description>Peak effect (Emax) within 0-4 hours of pulse, for treatment visits 2 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E0-4h: The Average of the Pulse Values Between 0 and 4 h for Every Treatment Visit</measure>
    <time_frame>0 - 4 hrs.</time_frame>
    <description>Average effect (E0-4h) of Pulse, for treatment visits 2 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Plasma Concentration</measure>
    <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
    <description>Maximum plasma concentration (Cmax) for AZD3199 doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC),</measure>
    <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity (AUC), for AZD3199 doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax:Time to Maximum Plasma Concentration</measure>
    <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
    <description>Time to maximum plasma concentration (tmax), for AZD3199 doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 :Terminal Half-life</measure>
    <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
    <description>Terminal half-life (t1/2),for AZD3199 doses</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 800 µg inhaled via single inhaler device (SID), single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 880 µg inhaled via SID, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 1400 µg inhaled via SID, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhaled via Turbuhaler inhaler and SID, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3199</intervention_name>
    <description>Inhaled via single inhaler device (SID)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3199</intervention_name>
    <description>Inhaled via Turbuhaler inhaler</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AZD3199 Placebo</intervention_name>
    <description>Inhaled via Turbuhaler inhaler and SID</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated written informed consent prior to any study specific
             procedures

          -  Men or women, age ≥ 18 years. Women must be of non-childbearing potential or stable on
             a highly effective contraceptive method for at least 3 months prior to Visit 1 and be
             willing to continue on the chosen contraceptive method throughout the study.

          -  Be a non-smoker or ex-smoker who has stopped smoking for &gt;6 months prior to study
             start

          -  A history of asthma for at least 6 months.

          -  Body Mass Index (BMI) 19-30 kg/m2

        Exclusion Criteria:

          -  Significant disease or disorder which, in the opinion of the Investigator, may either
             put the patient at risk because of participation in the study, or influence the result
             of the study, or the patient's ability to participate in the study

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the Investigator or history of hypersensitivity to β2-agonists in general or
             to AZD3199 and/or excipients

          -  Prolonged QTcF &gt; 450 msec or shortened QTcF &lt;340 msec

          -  History of alcohol/drug abuse or excessive intake of alcohol as judged by the
             Investigator

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <results_first_submitted>January 28, 2013</results_first_submitted>
  <results_first_submitted_qc>January 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2013</results_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>patients</keyword>
  <keyword>lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AZD-3199</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 39 patients were enrolled at 3 centres in Sweden. Of these, 26 patients were randomised to receive a treatment sequence consisting of 6 different treatments in random order. The number of patients randomised was well balanced across all the treatment periods. In total, 25 patients completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1400 μg / Placebo / 880 μg / 1200 μg / 800 μg / 300 μg</title>
          <description>AZD3199 1400 μg SID followed by Placebo followed by AZD3199 880 μg SID followed by AZD3199 1200 μg Turbuhaler inhaler followed by AZD3199 800 μg SID followed by AZD3199 300 μg Turbuhaler inhaler.</description>
        </group>
        <group group_id="P2">
          <title>880 μg / 1400 μg / 800 μg / Placebo / 300 μg / 1200 μg</title>
          <description>AZD3199 880 μg SID followed by AZD3199 1400 μg SID followed by AZD3199 800 μg SID followed by Placebo followed by AZD3199 300 μg Turbuhaler inhaler followed by AZD3199 1200 μg Turbuhaler inhaler.</description>
        </group>
        <group group_id="P3">
          <title>800 μg / 880 μg / 300 μg / 1400 μg / 1200 μg / Placebo</title>
          <description>AZD3199 800 μg SID followed by AZD3199 880 μg SID followed by AZD3199 300 μg Turbuhaler inhaler followed by AZD3199 1400 μg SID followed by AZD3199 1200 μg Turbuhaler inhaler followed by Placebo.</description>
        </group>
        <group group_id="P4">
          <title>300 μg / 800 μg / 1200 μg / 880 μg / Placebo / 1400 μg</title>
          <description>AZD3199 300 μg Turbuhaler inhaler followed by AZD3199 800 μg SID followed by AZD3199 1200 μg Turbuhaler inhaler followed by AZD3199 880 μg SID followed by Placebo followed by AZD3199 1400 μg SID.</description>
        </group>
        <group group_id="P5">
          <title>1200 μg / 300 μg / Placebo / 800 μg / 1400 μg / 880 μg</title>
          <description>AZD3199 1200 μg Turbuhaler inhaler followed by AZD3199 300 μg Turbuhaler inhaler followed by Placebo followed by AZD3199 800 μg SID followed by AZD3199 1400 μg SID followed by AZD3199 880 μg SID.</description>
        </group>
        <group group_id="P6">
          <title>Placebo / 1200 μg / 1400 μg / 300 μg / 880 μg / 800 μg</title>
          <description>Placebo followed by AZD3199 1200 μg Turbuhaler inhaler followed by AZD3199 1400 μg SID followed by AZD3199 300 μg Turbuhaler inhaler followed by AZD3199 880 μg SID followed by AZD3199 800 μg SID.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Total</title>
          <description>Total number of patients randomised and treated in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Emax: Maximum Value of FEV1 for Every Treatment Visits</title>
        <description>Peak effect (Emax) within 0-24 hours of FEV1, for treatment visits 2 to 7.</description>
        <time_frame>0-24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Emax: Maximum Value of FEV1 for Every Treatment Visits</title>
          <description>Peak effect (Emax) within 0-24 hours of FEV1, for treatment visits 2 to 7.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.788" spread="0.782"/>
                    <measurement group_id="O2" value="3.784" spread="0.724"/>
                    <measurement group_id="O3" value="3.756" spread="0.733"/>
                    <measurement group_id="O4" value="3.763" spread="0.744"/>
                    <measurement group_id="O5" value="3.847" spread="0.781"/>
                    <measurement group_id="O6" value="3.498" spread="0.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>E22-26h: The Average of the FEV1 Values Between 22 and 26 h for Every Treatment Visit</title>
        <description>Trough effect (E22-26h) will be computed from the repeated measurements collected after each single dose during 22-26 hours of FEV1 from visit 2 to 7.</description>
        <time_frame>22-26 hrs.</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>E22-26h: The Average of the FEV1 Values Between 22 and 26 h for Every Treatment Visit</title>
          <description>Trough effect (E22-26h) will be computed from the repeated measurements collected after each single dose during 22-26 hours of FEV1 from visit 2 to 7.</description>
          <population>PD analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.448" spread="0.709"/>
                    <measurement group_id="O2" value="3.453" spread="0.739"/>
                    <measurement group_id="O3" value="3.495" spread="0.730"/>
                    <measurement group_id="O4" value="3.448" spread="0.732"/>
                    <measurement group_id="O5" value="3.569" spread="0.761"/>
                    <measurement group_id="O6" value="3.310" spread="0.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>tEmax: Time to Maximum Value of FEV1 for Every Treatment Visit</title>
        <description>Time to peak effect (tEmax), within 0-24 hours of FEV1, for treatment visits 2 to 7.</description>
        <time_frame>0 - 24 hrs.</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>tEmax: Time to Maximum Value of FEV1 for Every Treatment Visit</title>
          <description>Time to peak effect (tEmax), within 0-24 hours of FEV1, for treatment visits 2 to 7.</description>
          <population>PD analysis set</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="0.50" upper_limit="10.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.50" upper_limit="22.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="0.25" upper_limit="24.00"/>
                    <measurement group_id="O4" value="1.000" lower_limit="0.25" upper_limit="22.00"/>
                    <measurement group_id="O5" value="4.000" lower_limit="0.25" upper_limit="24.00"/>
                    <measurement group_id="O6" value="10.000" lower_limit="0.00" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>E5min: The Value of FEV1 at 5 Min for Every Treatment Visit.</title>
        <description>Onset of effect (E5min), observed at 5 min. FEV1 for treatment visits 2 to 7.</description>
        <time_frame>FEV1 at 5 min</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>E5min: The Value of FEV1 at 5 Min for Every Treatment Visit.</title>
          <description>Onset of effect (E5min), observed at 5 min. FEV1 for treatment visits 2 to 7.</description>
          <population>PD analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.406" spread="0.743"/>
                    <measurement group_id="O2" value="3.449" spread="0.663"/>
                    <measurement group_id="O3" value="3.496" spread="0.692"/>
                    <measurement group_id="O4" value="3.489" spread="0.653"/>
                    <measurement group_id="O5" value="3.486" spread="0.723"/>
                    <measurement group_id="O6" value="3.188" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>E0-24h: The Average of the FEV1 Values Between 0 and 24 h for Every Treatment Visit</title>
        <description>Average effect over 0-24 hours of FEV1 (E0-24h), for treatment visits 2 to 7.</description>
        <time_frame>0 - 24 hrs</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>E0-24h: The Average of the FEV1 Values Between 0 and 24 h for Every Treatment Visit</title>
          <description>Average effect over 0-24 hours of FEV1 (E0-24h), for treatment visits 2 to 7.</description>
          <population>PD analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.489" spread="0.710"/>
                    <measurement group_id="O2" value="3.526" spread="0.737"/>
                    <measurement group_id="O3" value="3.537" spread="0.729"/>
                    <measurement group_id="O4" value="3.493" spread="0.707"/>
                    <measurement group_id="O5" value="3.636" spread="0.776"/>
                    <measurement group_id="O6" value="3.287" spread="0.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emax: Maximum Value of Pulse for Every Treatment Visits</title>
        <description>Peak effect (Emax) within 0-4 hours of pulse, for treatment visits 2 to 7.</description>
        <time_frame>0 - 4 hrs.</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Emax: Maximum Value of Pulse for Every Treatment Visits</title>
          <description>Peak effect (Emax) within 0-4 hours of pulse, for treatment visits 2 to 7.</description>
          <population>PD analysis set</population>
          <units>Beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.15" spread="11.10"/>
                    <measurement group_id="O2" value="64.36" spread="10.10"/>
                    <measurement group_id="O3" value="64.24" spread="9.27"/>
                    <measurement group_id="O4" value="64.84" spread="10.18"/>
                    <measurement group_id="O5" value="66.20" spread="12.38"/>
                    <measurement group_id="O6" value="64.12" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>E0-4h: The Average of the Pulse Values Between 0 and 4 h for Every Treatment Visit</title>
        <description>Average effect (E0-4h) of Pulse, for treatment visits 2 to 7.</description>
        <time_frame>0 - 4 hrs.</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>E0-4h: The Average of the Pulse Values Between 0 and 4 h for Every Treatment Visit</title>
          <description>Average effect (E0-4h) of Pulse, for treatment visits 2 to 7.</description>
          <population>PD analysis set</population>
          <units>Beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.85" spread="9.13"/>
                    <measurement group_id="O2" value="59.13" spread="8.83"/>
                    <measurement group_id="O3" value="59.07" spread="8.38"/>
                    <measurement group_id="O4" value="58.77" spread="8.66"/>
                    <measurement group_id="O5" value="59.73" spread="9.63"/>
                    <measurement group_id="O6" value="58.66" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Plasma Concentration</title>
        <description>Maximum plasma concentration (Cmax) for AZD3199 doses</description>
        <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Plasma Concentration</title>
          <description>Maximum plasma concentration (Cmax) for AZD3199 doses</description>
          <population>PK analysis set</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93846" spread="2.497151"/>
                    <measurement group_id="O2" value="5.81240" spread="2.497151"/>
                    <measurement group_id="O3" value="6.29560" spread="2.827910"/>
                    <measurement group_id="O4" value="3.01836" spread="1.294151"/>
                    <measurement group_id="O5" value="13.54120" spread="4.337208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC: Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC),</title>
        <description>Area under the plasma concentration-time curve from zero to infinity (AUC), for AZD3199 doses</description>
        <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>AUC: Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC),</title>
          <description>Area under the plasma concentration-time curve from zero to infinity (AUC), for AZD3199 doses</description>
          <population>PK analysis set</population>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.83501" spread="10.43729"/>
                    <measurement group_id="O2" value="20.21716" spread="10.19966"/>
                    <measurement group_id="O3" value="22.80110" spread="11.71379"/>
                    <measurement group_id="O4" value="10.25880" spread="4.886541"/>
                    <measurement group_id="O5" value="37.48982" spread="13.11484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax:Time to Maximum Plasma Concentration</title>
        <description>Time to maximum plasma concentration (tmax), for AZD3199 doses</description>
        <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax:Time to Maximum Plasma Concentration</title>
          <description>Time to maximum plasma concentration (tmax), for AZD3199 doses</description>
          <population>PK analysis set</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47000" lower_limit="0.2300" upper_limit="0.6200"/>
                    <measurement group_id="O2" value="0.48000" lower_limit="0.2700" upper_limit="0.6200"/>
                    <measurement group_id="O3" value="0.52000" lower_limit="0.2800" upper_limit="1.0300"/>
                    <measurement group_id="O4" value="0.52000" lower_limit="0.2500" upper_limit="0.5800"/>
                    <measurement group_id="O5" value="0.48000" lower_limit="0.2700" upper_limit="0.5800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 :Terminal Half-life</title>
        <description>Terminal half-life (t1/2),for AZD3199 doses</description>
        <time_frame>0 - 120 hrs for first two treatment visit 2 and 3 and 0 - 48 hrs for other treatment visits.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD3199 1400 μg</title>
            <description>AZD3199 1400 μg SID</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD3199 880 μg</title>
            <description>AZD3199 880 μg SID</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD3199 800 μg</title>
            <description>AZD3199 800 μg SID</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD3199 300 μg</title>
            <description>AZD3199 300 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD3199 1200 μg</title>
            <description>AZD3199 1200 μg Turbuhaler inhaler</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 :Terminal Half-life</title>
          <description>Terminal half-life (t1/2),for AZD3199 doses</description>
          <population>PK analysis set</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.97301" spread="24.65131"/>
                    <measurement group_id="O2" value="79.24210" spread="22.07879"/>
                    <measurement group_id="O3" value="103.7279" spread="113.8432"/>
                    <measurement group_id="O4" value="77.46496" spread="47.17895"/>
                    <measurement group_id="O5" value="88.99700" spread="46.23237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD3199 1400 μg</title>
          <description>AZD3199 1400 μg SID</description>
        </group>
        <group group_id="E2">
          <title>AZD3199 880 μg</title>
          <description>AZD3199 880 μg SID</description>
        </group>
        <group group_id="E3">
          <title>AZD3199 800 μg</title>
          <description>AZD3199 800 μg SID</description>
        </group>
        <group group_id="E4">
          <title>AZD3199 300 μg</title>
          <description>AZD3199 300 μg Turbuhaler inhaler</description>
        </group>
        <group group_id="E5">
          <title>AZD3199 1200 μg</title>
          <description>AZD3199 1200 μg Turbuhaler inhaler</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

